News | October 28, 2024
Strides Pharma Science reports Q2 FY25 consolidated PAT at Rs. 93.23 Cr
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Subscribe To Our Newsletter & Stay Updated
